Naropeine
Phase 3Small molecule
Naropeine is one of 29 small molecule programs targeting Hysterectomy. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
132 competitors in Hysterectomy
#DrugCompanyPhaseTrials
1Arcoxia
NovartisPhase 3
Elavil
AstraZenecaPhase 3
Cervidil
PfizerPhase 3
Tylenol
KKenvue Brands
Phase 3
Epsom Salt
FFresenius Kabi Oncology Ltd.
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Dilaudid
RRhodes Pharmaceuticals, L.P.
Phase 3
Ketalar
AAultman Health Foundation
Phase 3
Spravato
WWim Janssens
Phase 2
Depot Medroxyprogesterone Acetate
AbbViePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Naropeine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNantes University Hospital